X0306 4 2014-06-10 0 0001269021 PORTOLA PHARMACEUTICALS INC PTLA 0001252522 GALAKATOS NICHOLAS C/O MPM ASSET MANAGEMENT 200 CLARENDON STREET, 54TH FLOOR BOSTON MA 02116 1 0 0 0 Common Stock 2014-06-10 4 S 0 965 23.36 D 0 D Common Stock 2014-06-10 4 S 0 404 23.36 D 0 I See footnote Common Stock 19672 I MPM Asset Management Investors 2003 BVIII LLC Common Stock 85874 I MPM BioVentures III GmbH & Co. Beteiligungs KG Common Stock 30686 I MPM BioVentures III Parallel Fund, L.P. Common Stock 68320 I MPM BioVentures III, L.P. Common Stock 1016120 I MPM BioVentures III-QP, L.P. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.22 to $23.76, inclusive. The reporting person undertakes to provide Portola Pharmaceuticals, Inc., any security holder of Portola Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this Form 4. These shares were held by AAG Peakham LLC. Dr. Galakatos is a manager of AAG Peakham LLC. MPM BioVentures III GP, L.P. and MPM BioVentures III LLC ("MPM III LLC") are the direct and indirect general partners of MPM BioVentures III, L.P., MPM BioVentures III-QP, L.P., MPM BioVentures III GmbH & Co. Beteiligungs KG and MPM BioVentures III Parallel Fund, L.P. Dr. Galakatos is a Series A Member of MPM BioVentures III LLC and Manager of MPM Asset Management Investors 2003 BVIII LLC and shares voting and dispositive power over the shares held by MPM BioVentures III, L.P., MPM BioVentures III-QP, L.P., MPM BioVentures III GmbH & Co. Beteiligungs KG, MPM BioVentures III Parellel Fund, L.P. and MPM Asset Management Investors 2003 BVIII LLC. Dr. Galakatos disclaims beneficial ownership of the shares identified in this footnote except to the extent of his respective proportionate pecuniary interest in such share. /s/ Mike Ouimette, as attorney-in-fact 2014-06-11